This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2009 by Shandong University.
Recruitment status was:  Enrolling by invitation
Information provided by:
Shandong University Identifier:
First received: June 18, 2009
Last updated: October 13, 2009
Last verified: October 2009
Brain-derived neurotrophic factor (BDNF), originally known to be a member of the nerve growth factor family, has aroused attention as a modulator in visceral hyperalgesia recently. Visceral hypersensitivity is recognized as a clinical hallmark in IBS patients. So in this study, the investigators will focus on the role of BDNF in colonic hyperalgesia in IBS patients.

Irritable Bowel Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients

Resource links provided by NLM:

Further study details as provided by Shandong University:

Biospecimen Retention:   Samples With DNA
two mucosal biospecimens will be obtained from the rectosigmoid junction from each patient.

Estimated Enrollment: 30
Study Start Date: June 2009
Estimated Study Completion Date: November 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
irritable bowel syndrome
patients with diarrhea-predominant IBS will be enrolled in this group.
control group
patients with colon cancer or colon polyp will be enrolled as control group.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel habits in the absence of structural and biochemical abnormalities.

Inclusion Criteria:

  • Patients diagnosed with irritable bowel syndrome.

Exclusion Criteria:

  • Patients have similar clinical symptoms as IBS, yet there is morphologic changes in the intestine.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00925223

Sponsors and Collaborators
Shandong University
Study Director: Yanqing Li, PhD. MD. Department of Gastroenterology, Qilu Hospital, Shandong University
  More Information

Responsible Party: Yanqing Li, Qilu hospital of Shandong University Identifier: NCT00925223     History of Changes
Other Study ID Numbers: 2009SDU-QILU-G02
Study First Received: June 18, 2009
Last Updated: October 13, 2009

Keywords provided by Shandong University:
visceral hypersensitivity

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms processed this record on June 23, 2017